Consolidated revenue for Q1 of the fiscal year ending December 2026 was JPY 630,342 million (an 8.2% increase year-over-year), and net income attributable to owners of the parent for the quarter was JPY 98,348 million (a 15.7% increase year-over-year).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4578","jir_company_name":"Otsuka Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-04-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4578-20260428-01.pdf","jir_short_summary":"Consolidated revenue for Q1 of the fiscal year ending December 2026 was JPY 630,342 million (an 8.2% increase year-over-year), and net income attributable to owners of the parent for the quarter was JPY 98,348 million (a 15.7% increase year-over-year).","jir_summary":"### Performance Overview\nConsolidated revenue for Q1 of the fiscal year ending December 2026 was JPY 630,342 million (an 8.2% increase year-over-year), with revenue growth across all segments including the Pharmaceutical, Nutraceutical, Consumer Products, and Other Businesses. In particular, the Pharmaceutical segment saw increased sales of the antipsychotic 'Rexulti', the anticancer agent 'Lonsurf', long-acting injectable products 'Abilify Maintena\/Asmota', and the anti-APRIL antibody 'Bojact'. Operating profit was JPY 123,019 million (0.1% increase YoY), operating income was JPY 126,287 million (1.5% increase YoY), and net income attributable to owners of parent for the quarter was JPY 98,348 million (15.7% increase YoY), achieving profit growth. Research and development expenses were JPY 82,101 million (an increase of 4.7% YoY), mainly due to increased development costs for new antipsychotic Ulotaront, hematologic cancer treatment ASTX030, and phenylketonuria treatment repinatrabit.\n\n### Financial Position and Cash Flow Status\nTotal assets amounted to JPY 4,209,195 million (an increase of JPY 11,632 million from the previous consolidated fiscal year-end), total liabilities were JPY 1,035,161 million (a decrease of JPY 62,640 million), and total equity was JPY 3,174,033 million (an increase of JPY 74,272 million). Although current assets decreased, an increase in non-current assets drove the overall asset growth. Cash flow from operating activities increased year-over-year to JPY 108,882 million, cash flow used in investing activities totaled JPY 22,396 million, and cash flow used in financing activities was JPY 84,620 million. The main expenditures were treasury stock acquisitions, bond redemptions, and dividend payments.\n\n### Segment Results\nPharmaceutical segment revenue was JPY 453,822 million (8.6% increase YoY), and operating profit was JPY 114,307 million (1.9% decrease YoY). Prescriptions for the antipsychotic 'Rexulti' increased in the US and Japan, with sales of JPY 94,956 million (25.5% increase YoY). The anticancer agent 'Lonsurf' also saw revenue growth. The long-acting injectable 'Abilify' series posted substantial revenue gains. On the other hand, sales of the V2 receptor antagonist 'Samsca\/Zynarc' declined due to generic competition. Nutraceuticals segment revenue was JPY 138,935 million (5.8% increase YoY), and operating profit was JPY 15,875 million (5.6% increase YoY), with growth in the climate\/environmental risk, women\u2019s health, and Helcia Life categories. The Consumer Products segment performed solidly with revenue of JPY 7,924 million (7.3% increase YoY) and operating profit of JPY 5,398 million (13.0% increase YoY). The Other Businesses segment also showed revenue and profit growth.\n\n### M&A Overview\nOn March 27, 2026, Otsuka Pharmaceutical Co., Ltd. agreed to fully acquire Transcend Therapeutics, Inc., a US-based company developing fast-acting treatments for psychiatric and neurological disorders. The acquisition consideration includes a cash payment of USD 700 million plus up to USD 525 million in milestone payments. The acquisition is expected to be completed in Q2 of fiscal 2026. This will accelerate the development of novel therapies in the psychiatric and neurological fields, including PTSD, and is anticipated to expand the portfolio.","jir_financial_highlights":"Revenue: JPY 630,342 million (8.2% increase year-over-year)\nOperating Profit: JPY 123,019 million (0.1% increase year-over-year)\nOperating Income: JPY 126,287 million (1.5% increase year-over-year)\nQuarterly Profit: JPY 99,295 million (15.5% increase year-over-year)\nNet Income Attributable to Owners of Parent: JPY 98,348 million (15.7% increase year-over-year)\nResearch and Development Expenses: JPY 82,101 million (4.7% increase year-over-year)\nTotal Assets: JPY 4,209,195 million (Increase of JPY 11,632 million from previous fiscal year-end)\nTotal Liabilities: JPY 1,035,161 million (Decrease of JPY 62,640 million from previous fiscal year-end)\nTotal Equity: JPY 3,174,033 million (Increase of JPY 74,272 million from previous fiscal year-end)\nTreasury Stock Count (End of Period): 15,682,188 shares (Year-over-year increase (14,857,548 shares \u2192 15,682,188 shares))","jir_category":"","jir_hashtags":"#OtsukaHoldings, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Revenue: JPY 630,342 million (8.2% increase year-over-year)\nNet Income Attributable to Owners of Parent: JPY 98,348 million (15.7% increase year-over-year)\nResearch and Development Expenses: JPY 82,101 million (4.7% increase year-over-year)","jir_meta_title":"[Otsuka Holdings] Q1 2026 Earnings | Revenue JPY 630.3 Billion (+8.2% YoY)","jir_meta_description":"Otsuka Holdings' financial summary for Q1 fiscal year ending December 2026. Revenue grew 8.2% year-over-year to JPY 630,342 million, and net income attributable to owners of parent increased 15.7% to JPY 98,348 million. Revenue growth across all segments led by Pharmaceutical business.","jir_og_title":"[Otsuka Holdings] Q1 2026 Earnings | Revenue JPY 630.3 Billion (+8.2% YoY)","jir_og_description":"Q1 2026 results showing increased revenue and improved profitability. Growth in the Pharmaceutical segment and business expansion through M&A are progressing.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2025\\\",\\\"Q1 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[582840,630342],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2025\\\",\\\"Q1 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[124420,126287],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"quarterly_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2025\\\",\\\"Q1 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income Attributable to Owners of Parent\\\",\\\"data\\\":[84997,98348],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue by Category (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Business\\\",\\\"Nutraceutical Business\\\",\\\"Consumer Products Business\\\",\\\"Other Businesses\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Q1 2025\\\",\\\"data\\\":[417826,131355,7385,27068],\\\"backgroundColor\\\":\\\"#6f42c1\\\"},{\\\"label\\\":\\\"Q1 2026\\\",\\\"data\\\":[453822,138935,7924,30498],\\\"backgroundColor\\\":\\\"#fd7e14\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"research_development_expense_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Research and Development Expense Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2025\\\",\\\"Q1 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"R&D Expenses\\\",\\\"data\\\":[78382,82101],\\\"borderColor\\\":\\\"#17a2b8\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6875,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-43292","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n